The Role of Ruxolitinib in Secondary Acute Myelogenous Leukemia Evolving From Myeloproliferative Neoplasm
Condition: Secondary Acute Myelogenous Leukemia Evolving From Myeloproliferative Disorder Intervention: Drug: Ruxolitinib Sponsor: Seoul National University Hospital Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Acute Leukemia | Acute Myeloid Leukemia | Hospitals | Leukemia | Myeloproliferative Disorders